ASCO 2026 Puts Prostate and Bladder Cancer’s Old Playbook Under Pressure

Genitourinary cancers — encompassing prostate, bladder, kidney, and testicular malignancies — collectively affect more than 400,000 patients annually in the United States alone. Prostate cancer is the most commonly diagnosed cancer in men. Bladder cancer carries a high recurrence burden. Kidney cancer has been reshaped by immunotherapy combinations but faces unresolved second-line questions. What unites these diseases at ASCO 2026 is a consistent focus on treatment intensification in curable-intent settings, quality of life alongside survival, and the growing role of biomarker-driven selection.

The five trials below span localized high-risk prostate cancer treated before surgery, metastatic hormone-sensitive and castration-resistant disease, muscle-invasive bladder cancer, and second-line kidney cancer. Each addresses a point in the disease trajectory where the standard of care is actively under revision.

A Pre-Surgery Hormone Push Could Change High-Risk Prostate Cancer

Neoadjuvant Apalutamide + ADT Before Radical Prostatectomy in High-Risk Prostate Cancer (PROTEUS)

Late-Breaking Abstract LBA5002 | Trial: NCT03767244

Radical prostatectomy — surgical removal of the prostate — remains the standard curative-intent treatment for high-risk localized prostate cancer. But recurrence rates after surgery remain significant: a meaningful proportion of patients experience biochemical recurrence (a rising PSA level signaling residual disease) within five years. The question PROTEUS asks is whether intensifying hormonal therapy before the operation reduces that risk.

Androgen deprivation therapy (ADT) works by suppressing testosterone, which prostate cancer cells use as a growth signal. Apalutamide (Erleada) goes further — it is an androgen receptor pathway inhibitor (ARPI) that directly blocks the receptor inside the cancer cell, preventing it from responding even to low testosterone levels. PROTEUS randomizes patients with high-risk localized or locally advanced prostate cancer to six months of apalutamide plus ADT before radical prostatectomy, versus placebo plus ADT. The primary endpoints are pathologic complete response (complete disappearance of cancer in the surgical specimen) and metastasis-free survival.

This trial earned a coveted plenary slot — the highest-profile presentation format at ASCO, reserved for data with immediate practice-changing potential. Experts note that a positive result could position apalutamide-intensified neoadjuvant therapy as the new standard before prostatectomy, directly challenging the existing approach of ADT with radiation in this population.

Why it matters: High-risk localized prostate cancer is a disease where surgical cure is the stated goal — but recurrence undermines it in too many patients. A neoadjuvant intensification strategy that reduces recurrence risk and improves metastasis-free survival reframes the pre-surgical conversation and adds a precision medicine dimension to a setting that has long relied on surgery alone.

PARP Inhibitors Push Into Hormone-Sensitive Prostate Cancer

Enzalutamide + Talazoparib in HRR-Mutant Metastatic Hormone-Sensitive Prostate Cancer (TALAPRO-3)

Abstract LBA5000 | Trial: NCT04821622

Approximately 20–25% of patients with metastatic prostate cancer carry mutations in homologous recombination repair (HRR) genes — the DNA repair machinery that cancer cells use to survive the damage caused by treatment. The most recognized of these mutations are BRCA1 and BRCA2, but the broader HRR class includes ATM, CDK12, and others. Drugs called PARP inhibitors exploit this vulnerability: they block an alternative DNA repair pathway, causing cells that already have compromised HRR to accumulate lethal DNA damage.

TALAPRO-3 tests whether combining the PARP inhibitor talazoparib with enzalutamide (an androgen receptor blocker) improves outcomes in patients with HRR-deficient metastatic hormone-sensitive prostate cancer — meaning disease that has spread but has not yet become resistant to testosterone suppression. The trial delivers results at ASCO 2026, with particular attention on non-BRCA HRR-mutant patients, where PARP inhibitor activity has been less clearly established.

Why it matters: If talazoparib improves outcomes in the HRR-mutant mHSPC setting beyond what enzalutamide achieves alone, it deepens the biomarker-driven stratification of prostate cancer at the earliest point where it makes sense to act — before castration resistance develops. The non-BRCA data are especially clinically significant, as this group comprises the majority of HRR-mutant patients but has received less definitive guidance on PARP inhibitor use.

An ADC-Immunotherapy Combo Takes Aim at Bladder Cancer’s Old Standard

Enfortumab Vedotin + Pembrolizumab vs. Cisplatin Chemotherapy in Cisplatin-Eligible Muscle-Invasive Bladder Cancer (KEYNOTE-B15/EV-304)

Abstract LBA630 | Trial: NCT04700124

The standard treatment before bladder removal surgery for muscle-invasive bladder cancer has not fundamentally changed in decades: neoadjuvant cisplatin-based chemotherapy, followed by radical cystectomy. Cisplatin is effective but nephrotoxic — it damages the kidneys — and causes significant nausea and fatigue. Roughly half of patients are ineligible for it. For those who can receive it, pathologic complete response rates remain modest.

KEYNOTE-B15 enrolls cisplatin-eligible patients and tests whether the combination of enfortumab vedotin (an antibody-drug conjugate that delivers chemotherapy directly to cancer cells expressing Nectin-4) plus pembrolizumab (an immune checkpoint inhibitor) outperforms standard neoadjuvant cisplatin-gemcitabine chemotherapy. The combination has already demonstrated significant activity in cisplatin-ineligible bladder cancer populations and is now being tested head-to-head against the historical perioperative standard. KEYNOTE-B15 is the next step: a head-to-head confrontation with the historical standard that most eligible patients currently receive.

Why it matters: If enfortumab vedotin plus pembrolizumab outperforms cisplatin-based chemotherapy on overall survival and pathologic complete response in cisplatin-eligible patients, it replaces the perioperative standard across the entire muscle-invasive bladder cancer population — effectively ending the four-decade dominance of cisplatin-based neoadjuvant therapy in this setting.

Kidney Cancer’s Second-Line Playbook May Be Changing

Belzutifan + Lenvatinib vs. Cabozantinib in Second-Line Clear Cell Renal Cell Carcinoma (LITESPARK-011)

Abstract LBA417 | Trial: NCT04586231

First-line treatment for advanced clear cell renal cell carcinoma (kidney cancer) today pairs an immune checkpoint inhibitor with either another immunotherapy agent or a VEGF-targeting drug. When that first-line regimen fails, the second-line landscape has been dominated by cabozantinib — a multi-target kinase inhibitor that blocks VEGF receptor signaling and other growth pathways — but with limited durability.

LITESPARK-011 introduces a mechanistically distinct second-line option. Belzutifan (Welireg) targets HIF-2α — a protein that kidney cancer cells use to adapt to low-oxygen environments, driving aggressive growth and treatment resistance. Combining belzutifan with lenvatinib (a VEGF pathway blocker) attacks the disease from two directions simultaneously. Data presented at ASCO GU 2026 showed the combination achieved a median progression-free survival of 14.8 months versus 10.7 months with cabozantinib, nearly doubling the duration of response. Overall survival data are presented at ASCO 2026.

Why it matters: LITESPARK-011 is the first phase 3 trial to validate HIF-2α inhibition as a second-line strategy in kidney cancer. A confirmed overall survival benefit would displace cabozantinib as the default second-line choice and establish HIF-2α/VEGF dual blockade as the new post-immunotherapy standard — with implications for sequencing and future combination development.

One Prostate Cancer Drug May Be Easier on the Brain Than Another

Cognitive Effects of Darolutamide vs. Enzalutamide in Advanced Prostate Cancer (ARACOG)

Abstract 5005 | Trial: NCT04141644

Darolutamide (Nubeqa) and enzalutamide (Xtandi) are both androgen receptor pathway inhibitors approved for multiple prostate cancer settings. Both extend survival. But they differ structurally: enzalutamide crosses the blood-brain barrier — the protective layer that separates the bloodstream from brain tissue — while darolutamide has very limited central nervous system penetration. That structural difference has long been hypothesized to translate into a meaningful difference in cognitive side effects, since AR signaling in the brain influences cognitive function.

ARACOG (AFT-47) is the first randomized prospective head-to-head trial designed to answer this question directly. The phase 2 trial uses objective neuropsychological testing — not just patient-reported questionnaires — to measure cognitive function over 24 weeks in patients randomized to darolutamide versus enzalutamide. Pre-meeting data from the ASCO Post confirm that patients on darolutamide experienced significantly less objectively assessed cognitive decline, and that a meaningful proportion of enzalutamide-treated patients crossed over to the alternate therapy — a real-world signal of tolerability differences.

Why it matters: Tens of thousands of patients take androgen receptor pathway inhibitors for years. Cognitive effects are among the most patient-reported concerns with enzalutamide, but they have been difficult to quantify in standard trial endpoints. Objective neuropsychological data from a randomized comparison provide the evidence base clinicians and patients need to make informed treatment choices — and may shift prescribing toward darolutamide in patients with baseline cognitive concerns.

The Bigger Picture in GU Oncology at ASCO 2026

Two philosophical currents run through this year’s GU slate. The first is intensification: PROTEUS adds an ARPI before surgery; KEYNOTE-B15 adds an ADC-immunotherapy combination before bladder removal; TALAPRO-3 adds a PARP inhibitor to standard hormonal therapy at the earliest metastatic stage. In each case, the question is whether earlier and stronger treatment produces outcomes that later, reactive treatment cannot recover. The second current is quality of life as a co-equal endpoint: ARACOG’s cognitive comparison reflects a maturing field that recognizes that living longer means little if cognitive function is significantly impaired. ASCO 2026 puts both dimensions on the table simultaneously.

Author

Bernice Lottering